For the quarter ended December 2024, Viatris (VTRS) reported income of $3.53 billion, down 8.1% over the identical interval final 12 months. EPS got here in at $0.54, in comparison with $0.61 within the year-ago quarter.
The reported income represents a shock of -2.04% over the Zacks Consensus Estimate of $3.6 billion. With the consensus EPS estimate being $0.57, the EPS shock was -5.26%.
Whereas buyers carefully watch year-over-year modifications in headline numbers — income and earnings — and the way they examine to Wall Road expectations to find out their subsequent plan of action, some key metrics at all times present a greater perception into an organization’s underlying efficiency.
As these metrics affect top- and bottom-line efficiency, evaluating them to the year-ago numbers and what analysts estimated helps buyers mission a inventory’s value efficiency extra precisely.
Right here is how Viatris carried out within the simply reported quarter when it comes to the metrics most generally monitored and projected by Wall Road analysts:
- Complete Web Gross sales: $3.52 billion versus the three-analyst common estimate of $3.59 billion. The reported quantity represents a year-over-year change of -8.1%.
- Different revenues: $12.70 million versus $11.47 million estimated by three analysts on common. In comparison with the year-ago quarter, this quantity represents a +11.4% change.
- Web Gross sales- JANZ: $334.50 million versus the two-analyst common estimate of $366.35 million. The reported quantity represents a year-over-year change of -10.2%.
- Web Gross sales- Rising Markets: $513 million versus the two-analyst common estimate of $538.93 million. The reported quantity represents a year-over-year change of -17.1%.
- Web Gross sales- Developed Markets- Manufacturers: $1.10 billion in comparison with the $1.21 billion common estimate primarily based on two analysts. The reported quantity represents a change of -16.3% 12 months over 12 months.
- Web Gross sales- JANZ- Manufacturers: $172.40 million versus the two-analyst common estimate of $198.33 million. The reported quantity represents a year-over-year change of -13.6%.
- Web Gross sales- JANZ- Generics: $162.10 million versus $168.03 million estimated by two analysts on common. In comparison with the year-ago quarter, this quantity represents a -16.2% change.
- Web Gross sales- Rising Markets- Manufacturers: $372.30 million versus $401.94 million estimated by two analysts on common. In comparison with the year-ago quarter, this quantity represents a -0.6% change.
- Web Gross sales- Rising Markets- Generics: $140.70 million versus the two-analyst common estimate of $171.99 million. The reported quantity represents a year-over-year change of -42.5%.
- Web Gross sales- Higher China: $521.80 million in comparison with the $553.04 million common estimate primarily based on two analysts. The reported quantity represents a change of +1.3% 12 months over 12 months.
- Web Gross sales- Developed Markets: $2.15 billion in comparison with the $2.17 billion common estimate primarily based on two analysts. The reported quantity represents a change of -7.5% 12 months over 12 months.
- Web Gross sales- Developed Markets- Generics: $1.04 billion versus $1.06 billion estimated by two analysts on common. In comparison with the year-ago quarter, this quantity represents a -27.1% change.
View all Key Company Metrics for Viatris here>>>
Shares of Viatris have returned -16.6% over the previous month versus the Zacks S&P 500 composite’s -2.4% change. The inventory at the moment has a Zacks Rank #4 (Promote), indicating that it may underperform the broader market within the close to time period.
7 Finest Shares for the Subsequent 30 Days
Simply launched: Specialists distill 7 elite shares from the present listing of 220 Zacks Rank #1 Robust Buys. They deem these tickers “Most Doubtless for Early Worth Pops.”
Since 1988, the total listing has overwhelmed the market greater than 2X over with a median acquire of +24.3% per 12 months. So make sure you give these hand picked 7 your quick consideration.
Viatris Inc. (VTRS) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.
